A multifaceted peer reviewed journal in the field of Pharm Analysis and Pharmaceutics www.phmethods.net | www.journalonweb.com/phm

# Stability Indicating UV Spectrophotometric Method For Linagliptin and Metformin in Pharmaceutical Dosage Form

Sarif Niroush Konari<sup>\*1</sup>, Jane T. Jacob<sup>2</sup>, Vipin Prakash<sup>1</sup>

<sup>1</sup>Department of Pharmaceutical Analysis, JDT Islam College of Pharmacy, Calicut – 673012, Kerala, INDIA.

<sup>2</sup>Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences, Nitte University Deralakatte, Mangalore – 575018, Karnataka, INDIA.

#### ABSTRACT

**Introduction:** Linagliptin and metformin are newly introduced FDA drug combination for the treatment type 2 diabetic patients. This study reveals the development of three methods for the UV spectrophotometric simultaneous estimation of linagliptin and metformin in pharmaceutical dosage and forced degradation studies on four different stress conditions. **Methods:** Development of method was based upon simultaneous equation, absorbance ratio and absorbances correction method with a simple solvent system of distilled water. Absorption maxima was found to be 230.4nm, 294.4nm for metformin and linogliptin respectively without mutual interference. Isobestic point for both drugs was chosen at 250.4 mm. Stabilty studies were carried out on acid, alkaline, peroxide and thermal stress conditions. **Conculsion:** Degradation studies reveals that method capability on different stress condition. This method obeyed Beer's law in the concentration range of 2-14 µg /ml for metformin and 10-40 µg /ml for linogliptin. The results of the analysis has been validated statistically.

Method proven to be rapid, precise and cost effective for the routine analysis in pharmaceutical dosage form. Forced degradation outcomes can be used for the development of stable formulation and helps in the planning of proper storage requirement.

Key words: Forced degradation studies, ICH guidelines, Simultaneous, linagliptin, Metformin.

#### Correspondence:

Sarif Niroush Konari Department of Pharmaceutical Analysis, JDT Islam College of Pharmacy, Calicut – 673012, Kerala, INDIA. Phone no: 09947758508

E-mail: niroush@gmail.com DOI: 10.5530/phm.2017.8.19

# **INTRODUCTION**

Linagliptin and metformin are regularly prescribed as a fixed drug combination for the treatment type 2 diabetes. Linagliptin assist pancreas to release more insulin and also indicats the liver to stop producing glucose when high glucose level present blood thereby it maintains glucose level of the diabetic patient. Metformin reduces the absorption of glucose from the stomach, bring down the release of stored glucose from the liver. Linagliptin belong to new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs and chemically<sup>1</sup> is 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]- 2, 3, 6, 7tetrahydro-1 H-purine-2, 6-dione. Metformin<sup>2</sup> chemically N, N-diethyl imido dicarbonimidic diamide hydrochloride and belongs to the biguanide class of anti-diabetic drug.

Literature studies reveals that no stability indicating simultaneous RP-HPLC and UV method with degradation studies for titled drug combinations were not reported so far till date with simple solvent system like distilled water.<sup>3-5</sup> Though LC published article are available, this work stands apart by being simple interms of solvent consumption.Development of method was based upon three different approaches like simultaneous equation, absorbance ratio and absorbances correction method. Moreover LOD and LOQ establishes rapid and sensitive of the developed technique. Robustness study was performed on two different parameters demonstrates method capacity to withstand the deliberate changes. Forced degradation study carried out by UV spectroscopy at four different stress state reveals that method is stable to specified period of time

# **MATERIAL AND METHOD**

# **Regents and chemicals**

Linagliptin and metformin was obtained from Mylan laboratories laboratories limited, hyderbad, India respectively. Formulation was procured from the local market having strength of 2.5 and 500 mg of Linagliptin and metformin respectively.

#### Instrument

Systronics spectrophotometer 2202 UV/Visible double beam spectrophotometer with spectral band width of 2 nm, 0.5 nm of wavelength was used for all spectral measurements using a pair of 1cm matched quartz cell.

#### **Selection of diluents**

Diluent suitable for both Linagliptin and metformin was found to be distilled water.Metformin was freely soluble but linagliptin made solubilished in distilled water with vigourous shaking.

#### **Parameter fixations**

In the UV region of 400-200 nm, absorption maxima was found to be 230.4 nm and 294.4 nm was for metformin, Linogliptin respectively. Isobestic point for both drugs was chosen at 250.4 nm.

#### Stock and working solution

A quantity of 50 mg each of Linogliptin, metformin were weighed into a 50 ml separate standard flask and made up to the mark with diluent. From the stock, solution 5 ml was pipetted into 50ml volumetric flask and diluted with the diluents to a get concentration of  $100\mu g/ml$ . Subsequent dilution was made with diluent to get a concentration of  $2-14\mu g/ml$ ,  $10-40\mu g/ml$  for metformin and Linogliptin respectively.

# Standard and sample preparation

The developed procedure was extended to formulation of Linogliptin and metformin.Tablets were crushed to a fine powder, powder equivalent to 50 mg was transferred to a 50 ml volumetric flask, dissolved in distilled water and then the solution was made up to the mark with the same and filtered through whatman filter paper no 42. Further dilution are done to get a concentration of  $100\mu$ g/ml. Subsequent dilutions of this solution were made to a get final concentration of  $10 \mu$ gl/ml and  $40\mu$ g/ ml of metformin and Linogliptin respectively for method one and two.<sup>6</sup> Final dilution for method three<sup>7</sup> was made to get concentration of  $3 \mu gl/$  ml and  $40\mu g/ml$  of metformin and Linogliptin respectively.

# Method 1:vierordt's method of simultaneous determination

$\mathbf{Cx} = \mathbf{A_2} \mathbf{ay_1} - \mathbf{A_1} \mathbf{ay_2} / \mathbf{ax_2} \mathbf{ay_1} - \mathbf{ax_1} \mathbf{ay_2}$	
---	--

 $Cy = A_1 a x_2 - A_2 a x_1 / a x_2 a y_1 - a x_1 a y_2 \dots (2)$ 

Where,  $A_1$  and  $A_2$  are absorbance of mixture at 230.4 nm  $(\lambda_1)$  and 294.4 nm  $(\lambda_2)$  respectively,  $ax_1$  and  $ax_2$  are absorptivities of metformin at  $\lambda_1$  and  $\lambda_2$  respectively,  $ay_1$  and  $ay_2$  are absorptivities of linagliptin at  $\lambda_1$  and  $\lambda_2$  respectively, Cx and Cy are concentrations of metformin and linagliptin respectively

# Method 2:Absorbance ratio method (Q-Absorbance method)

$$\mathbf{C}_{\mathbf{X}} = \frac{\mathbf{Q}_{\mathrm{M}} - \mathbf{Q}_{\mathrm{Y}}}{\mathbf{Q}_{\mathrm{X}} - \mathbf{Q}_{\mathrm{Y}}} \times \frac{\mathbf{A}_{1}}{a_{\mathrm{X}1}} \qquad \qquad \mathbf{C}_{\mathbf{Y}} = \frac{\mathbf{Q}_{\mathrm{M}} - \mathbf{Q}_{\mathrm{X}}}{\mathbf{Q}_{\mathrm{Y}} - \mathbf{Q}_{\mathrm{X}}} \times \frac{\mathbf{A}_{1}}{a_{\mathrm{Y}1}}$$

 $Q_{x} = A_{2}/A_{1}$   $Q_{x} = ax_{2}/ax_{1}$   $Q_{y} = ay_{2}/ay_{1}$ 

Where,  $C_x$  is the concentration of metformin and  $C_y$  concentration of linagliptin,  $A_1 \& A_2$  are the absorbance of the mixture at  $\lambda_1$  nm (250.4 nm isobetic point) &  $\lambda_2$ nm (294.4nm) respectively;  $a_{x1}$  and  $a_{y1}$  are absorptivity of metformin and linagliptin respectively at  $\lambda_1$  nm ;  $a_{x2}$  and  $a_{y2}$  are absorptivity of metformin and linagliptin respectively at  $\lambda_2$  nm.

#### Method 3: Absorbance correction method

```
A=abc

Cx=A_1/ab

Cx= A_1/ax_1 * b .....(1)

A<sub>2</sub>=A metformin + A Linagliptin

A<sub>2</sub>=(ay<sub>2</sub>*cy*b)+(ax<sub>2</sub>*cx*b)

A<sub>2</sub>=(ay<sub>2</sub>*cy*)+(ax<sub>2</sub>*cx*)
```

#### Cy=[A<sub>2</sub>-(ax<sub>2</sub>\*cx)]/ay<sub>2</sub> .....(2)

where  $A_1$ ,  $A_2$  are absorbance of mixture at 230.4 nm ( $\lambda_1$ ) and 294.4 nm ( $\lambda_2$ ), respectively,  $ax_1$  and  $ax_2$  are absorptivities of metformin at  $\lambda_1$  and  $\lambda_2$ , respectively,  $ay_1$  and  $ay_2$  are absorptivities of linagliptin at  $\lambda_1$  and  $\lambda_2$ , respectively,  $c_x$  and  $c_y$  are concentrations of metformin and linagliptin respectively.

#### Forced degradation study<sup>8-12</sup>

Forced degradation is a procedure that includes the degradation of drug molecule at different stress conditions that can be used to find out the stability of the drug substance.

### **Objectives of forced degradation study**

To expose the degradation mechanisms at different stress conditions of the drug formulation

To check the intrinsic stability of a drug molecule in dosage form

To purpose stability indicating nature of a developed techniques

#### **Acidic and Alkaline degradation**

From the working solution, 1.4 ml of metformin and 4 ml of linagliptin was taken into separate 10 ml flasks and degradation studies were carried out. 3 ml of 0.1N HCl was added to flasks containing solution of metformin,linagliptin for acidic condition and same procedure repeated

with 3ml of 0.1N NaOH for alkaline condition. Then, the volumetric flasks were kept at 60-70°C in reflux condition 15 minutes in dark for acid and alkaline condition respectively. Finally, volume made up to 10 ml with diluents and absorbance was measured.

#### **Oxidative and thermal degradation**

From working solution, transfer 1.4 ml of metformin and 4 ml of linagliptin into separate flask and to each 1ml of 6 % w/v of hydrogen peroxide was added and the volume was made up to 10 ml the mark with diluent. Then, the volumetric flasks were kept in dark for 15 min and absorbance was measured.

Thermal study was carried out by taking 1.4 ml of metformin and 4 ml of linagliptin from working solution into separate flasks 10 ml flask. Then kept in hot air oven at 90°C for 15 min and vol was made up to 10 ml with diluents and absorbance was measured.

#### Method Validation 12-14

#### Accuracy

The accuracy of the method was determined by preparing solutions at different concentrations such as 80%, 100% and 120% in which the amount of formulation was kept constant and the amount of pure drug was varied at three different levels. The solutions were prepared in triplicates and the accuracy was indicated by percentage of recovered amount of drug.

#### Precision

Precision studies were performed for intermediate/ruggdness and intraday. Ruggdness were carried out by using different UV instrument. Aliquot portions of stock solution of both drug was further diluted to get concentration of  $2,10\mu$ g/ml for metformin and for linagliptin  $10,40\mu$ g/ml.

#### Linearity

Linearity was established in the range of  $2-14 \mu g/ml$  for metformin and  $10-40 \mu g/ml$  of linagliptin. The correlation coefficient of the linearity was found to be 0.999 at each wavelength for both drugs. Residual plot displayed excellent linearity.

#### **Stability of analytical solution**

The stability of analytical solution for the standard and sample preparation was determined by taking the absorbances at 4, 8, 12, 24 and 48 h.

#### Specificity study

Specificity study was conducted by comparing the spectrum of tablet solution and that of standard solution. It was noted that there was no interference of the excipients in the formulations. Forced degradation studies also confirms the specificity of the developed method.

#### **Robustness study**

It was conducted by the minor variations in the optimized parameters like pH of solvent system and the absorption maxima of the determination. It was observed that there were no much changes in the absorption value of the two titled drugs.

# LOD and LOQ

LOD is the lowest amount of analyte in a sample that can be detected, but not necessarily quantitated under the optimized conditions. Limit of detection can be calculated using the following equation as per ICH guidelines.

#### $LOD = 3.3 \times F/S$

 ${\rm F}=$  Standard deviation of the response, S = Slope of the corresponding calibration curve.

LOQ is the lowest concentration of analyte in a sample that can be determined with the acceptable precision and accuracy under optimized conditions. Limit of quantification can be calculated using the following equation as per ICH guidelines.

 $LOQ = 10 \times F/S$ 

 ${\rm F}=$  Standard deviation of the response, S = Slope of the corresponding calibration curve.


#### RESULT

#### **Forced degradation studies**

Metformin degraded up to 19.72 % that was slightly high in contrast to linagliptin under acidic condtion whereas as in alkali condition linagliptin degraded little more than metformin. Moreover Slight shift of lamda max was detected for linagliptin under alkaline forced degradation study. This may be due to break down of ionsiable functional group present in the titled drug molecule.linagliptin undergone high degradation under peroxide stress condition in comparision to metformin and may be due electron transfer mechanism to form reactive cations and anions. Thermal degradation explained on the basis of arrhenius equation and linagliptin was slightly sensitive to thermal conditions.forced degradation studies proves that these methods are apt for its proposed use. Forced degradation results can be used for the development of stable formulation and helps in designing proper storage requirement (Table 1 & Figure 1,2).

### **Optimization and validation of method**

Three methods were used for the estimation of metformin and linagliptin in pharmaceutical dosage form with a simple solvent system (Table 2 & Figure 3, 4).Validation studies were carried out on different parameters









Table 1: Forced degradation study								
Stress condition	Meformin				linagliptin			
	Amount found (µg/ml)	%Drug degraded	% Drug obtained	Amount found (µg/ml)	%Drug degraded	% Drug obtained		
Acid (0.1N) 15 min with reflux condition	11.23	19.72	80.27	33.82	15.42	84.57		
Alkali (0.1N) 15 min with reflux condition	13.70	2.09	97.90	35.47	11.31	88.68		
Hydrogen peroxide (6%w/v) 15 min Without reflux condition	13.46	3.83	96.16	33.39	16.51	83.48		
Thermal 60 min 80-90°c	13.60	2.78	97.21	33.42	16.39	83.60		

able 2: Ana	lysis of sample	e preparations	;	
Methods	Drug	Label claim (mg)	Amount found (mg)	% label claim
Method 1	metformin	500	491.12	98.22
	linagliptin	2.5	2.46	98.60
Method 2	metformin	500	490.68	98.13
	linagliptin	2.5	2.49	99.79
Method 3	metformin	500	495.88	99.17
	linagliptin	2.5	2.46	98.59

Average mean of six determinations

as per ICH guideline such as recovery study,intraday and intermediate precision and range, LOD and LOQ, Specificity and robustness study. Linearity was established at seven different concentrations for both titled drugs with good correlation coefficient and residual plots. Residual are the vertical line between regression line and recorded data.Residual plot does not displayed obvious pattern and relative smaller in size.Overall perdited y value and observed y value are closer that indicate good linear relation ship between x and y variables (Figure 5, 6). and Inter day precision were carried out using same optimized conditions and and RSD<sup>15-16</sup> was less than 2 % (Table 4). LOD and LOQ indicate that method was highly sensitive and fast (Table 5). The method was found highly specific since there is no interference form the excipients of the formulations. Analytical solution was found stable up to 48 hrs on stable storage condition. The method has been highly robust since deliberate changes in the optimized parameters does not effect to a certain extent (Table 6).

Accuracy or recovery conducted at three different levels (Table 3). Intra







Figure 4: Overlay spectrum of metformin and linagliptin.

Table 3: Recover	y Study					
Drug	Amount taken µg/ml	Amount added µg/ml	Recovery level in %	Total Amount of drug μg/ ml±SD	Amount recovered	% Recovery*
metformin	2	1.6	80	3.61±0.08	1.60	100.08
		2	100	3.98±0.07	1.98	99.32
		2.4	120	4.43±0.06	2.38	99.42
linagliptin	10	8	80	17.73±0.27	7.73	96.72
		10	100	19.66±0.47	9.66	96.66
		12	120	12.09±0.29	12.0	100.75

Average mean of three determinations in each level

Table 4 : Precision study									
Precision	metformin					linagliptin			
	2μg/m	l (n=6)	10µg/n	nl(n=6)	10µg/m	nl (n=6)	40µg/ı	nl(n=6)	
	mean	%RSD	mean	%RSD	Mean	%RSD	mean	%RSD	
Intermidate/ Ruggdness	0.245	1.02	0.971	1.10	0.255	1.02	1.21	0.11	
Intraday	0.238	0.63	0.969	0.91	0.252	0.75	1.32	0.09	
Method	0.232	0.68	0.958	0.89	0.242	0.71	1.29	0.08	






Figure 5: Metformin residual plot.

Table 5: LOD and LOQ				
Drug μg/ml	LOD	LOQ		
Meformin	0.34	1.71		
linagliptin	1.03	5.18		

Table 6: Robustness study						
Parameters	Modifications	Absorbance		% RSD		
		metformin	linagliptin	metformin	linagliptin	
Mobile phase	pH 6.5	0.407	0.419			
	Optimized	0.422	0.435	1.83	1.92	
	pH 7.5	0.417	0.424			
Absorption maxima	+2 nm	0.418	0.432			
	Optimized nm	0.422	0.435	0.49	0.58	
	- 2nm	0.421	0.43			

#### CONCULSION

The developed spectroscopic methods are found to be rapid, cost effective, accurate and precise and can be used for routine analysis of metformin and linagliptin. The developed methods were validated as per ICH guidelines. The % RSD for the validation parameters was found to be less than 2%. Hence proposed method may be used for routine analysis of these drugs in pharmaceutical dosage forms. Stability indicating nature of the method well established for a specified period which indirectly point out the method competence under different stress condition and thereby useful for the designing of storage requirement of the formulation. This work can be extended to characterize unknown degradents with integrated approach.

#### ACKNOWLEDGEMENT

Authors are grateful to Mylan Laboratories Limited, Hyderabad for providing the gift sample A special acknowledges to Mr. Sreekanth Nadig, Manager – Analytical R&D of Mylan Laboratories Limited for his continuous encouragement.

#### **CONFLICT OF INTEREST**

None

#### **ABBREVIATIONS USED**

UV spectroscopy: Ultra violet spectroscopy; ICH-International Conference on Harmonisation; DPP: dipeptidyl peptidase; LOD: Limit of detection; LOQ: Limit of quantification.


#### REFERENCES

- Drug bank of linogliptin. Available from: https://www.drugbank.ca/drugs/ DB08882. Acessed:on March, 2016
- Government of India, Ministry of Health and Family Welfare, Indian Pharmacopoeia, The Controller of Publication, New Delhi, 2010, pp. 1657-1660
- Simultaneous determination of linagliptin and metformin by reverse phasehigh performance liquid chromatography method: An application in quantitative analysis of pharmaceutical dosage forms. J Adv Pharm Technol Res. 2015;6(1):25-8. https://doi.org/10.4103/2231-4040.150368; PMid:25709966 PMCid:PMC4330608.
- Spectrophotometric methods for the determination of linagliptin in binary mixture with metformin hydrochloride and simultaneous determination of linagliptin and metformin hydrochloride using high performance liquid chromatography. Int J Biomed Sci. 2013;9(1):41-7. PMid:23675288 PMCid:PMC3644414.
- RP-HPLC method for simultaneous estimation of metformin and linagliptin in tablet dosage form. Rasayan J Chem. 2015;8(4):426-32
- Beckett AH, Stenlake JB. Pharmaceutical Chemistry part 2. 4thed, CBS publisher and distributor. New Delhi, 2004,pp.284-6.

- Absorbance correction method for estimation of telmisartan and metoprolol succinate in combined tablet dosage forms. Pharm Methods. 2012;3(2):106-11. https://doi.org/10.4103/2229-4708.103891 ; PMid:23781489 PMCid:PMC3658092.
- Stability Indicating validated RP-HPLC Technique for the Analysis of Multi component Anti diabetic Drug Combos in Pharmaceutical Dosage Forms. journal of karbala international journal of modern sciences. 2015;1(1):39-48. DOI: http:// dx.doi.org/10.1016/ j.kijoms.2015.06.002.
- Stability indicating validated UPLC technique for the simultaneous analysis of raltegravir and lamivudine in pharmaceutical dosage forms. HIV & AIDS Review. 2016. 15:161–169.DOI :www.sciencedirect.com/science/article/pii/ S1730127016300571
- Blessy M, Ruchi PD, Prajesh NP, Agrawal YK. Development of forced degradation and stability indicatingstudies of drugs. A review, J Pharm Anal. 2014;4:159-65. https://doi.org/10.1016/j.jpha.2013.09.003.
- 11. Reynolds DW, Facchine KL, Mullaney JF. Available guidance and best Practices

for Conducting forced degradation Studies. Pharm Techno. 2002;l26(2):48-56.

- ICH Q1A (R2), Stability Testing of New Drug Substances and Products, 2003. Available from: ww.ich.org/file admin/Public./ICH\_Products/../Q1A\_R2/./Q1A\_ R2\_Guideline.p. Acessed:on June, 2012.
- Application of Analytical Validated High-Performance Thin-Layer Chromatographic Technique for the Multicomponent Analysis of Cardiovascular Drug Combos in Pharmaceutical Dosage Form." J P C. 2015;28(5):354–61. DOI: 10.1556/1006.2015.28.5.3. https://doi.org/10.1556/1006.2015.28.5.3.
- ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology, 2005. Available from: www.ich.org/.../validation-of-analytical-procedures-text-andmethodology.html. Accessed: on May, 2012.
- Richard J, Sundar Rao PSS. An introduction to prentice hall of India.New Delhi 2010.pp.66-80.
- Charles HB, Corrinne P. Understandable statistics, 3rd edition, D.C. Heath and company, Lexington, Toronto, Canada. 1987:pp.390-5.



#### **SUMMARY**

- This contains overlay spectrum of metform and linagliptin along with binary combination mix of two titled drugs.
- This spectroscopic analytical technique are found to be rapid, cost effective, accurate and precise and can be used for routine analysis of metformin and linagliptin.

### **ABOUT AUTHORS**



**Dr. Sarif Niroush Konari:** Currently working as professor under the department of pharmaceutical analysis, at JDT Islam College of Pharmacy, His area of interest is in analytical method development and validation of newer drug combinations and recently completed doctorate in pharmaceutical analysis under faculty of pharmaceutical sciences from Nitte University. He is author of well reputed elsevier publications and also reviewer of reputed journal.



**Dr. Jane T. Jacob:** Currently working as a associate professor under the department of pharmaceutical chemistry, NGSM Institute of Pharmaceutical Sciences, Nitte University Deralakatte, and Mangalore. Her area of interest is in analytical method development and validation of newer drug combinations. She is the well-recognized Ph.D guide in Pharmaceutical Sciences under Nitte University, Mangalore and also postgraduate teacher. She is also the author of well reputed elsevier publications.



**Vipin prakash:** Currently working as professor under the department of pharmaceutical analysis, at JDT Islam college of Pharmacy, His area of interest is in analytical method development and validation and currently pursuing doctorate in analytical method development under JNTU University, Hyderabad.